List of Personalized Medicine Companies in North Carolina - 4

BioCytics via the Human Applications Lab is focused on bringing personalized oncology treatments to the market. BioCytics has an ongoing IRB-approved clinical trial (BioCytics 0001; NCT00571389) that allows for the collection and study of blood and tissue samples from consenting cancer patients. We are incubated within Carolina BioOncology - a preferred cancer treatment and Phase I drug testing facility. BioCytics was founded by Dr. John Powderly, MD, medical board certified oncologist and a certified physician investigator (CPI), who is also president of Carolina BioOncology Institute (CBOI).

BioSkryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou's laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings ("LabCorp") and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric's second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.